The safety and preliminary efficacy of the addition of an aqueous curcumin-cyclodextrin complex (CDC) solution to graft perfusion solution is studied. CDC has proved safe and highly effective in preventing primary graft non-function, delayed graft function and chronic dysfunction in pre-clinical kidney transplantation animal models. The hypothesis is that addition of CDC to the graft perfusion solution will decrease the incidence of delayed graft function in human kidney transplantation subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
20
2 ml of CDC 12/mg/ml is added to 1 l of UW solution. 500 ml of of this solution is used for flushing the kidney allograft prior to transplantation
500 ml of UW solution is used for flushing the kidney allograft prior to transplantation
Helsinki University Central Hospital
Helsinki, Finland
RECRUITINGDelayed Graft Function
Time frame: 7 days
Primary non-function
Time frame: 1 year
Acute rejection
Time frame: 1 year
Graft function eGFR
Time frame: 30 days, 90 days
Graft Survival
Time frame: 1 year
Patient Survival
Time frame: 1 year
Length of stay in hospital
Time frame: upto 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.